Freddy E. Escorcia, M.D., Ph.D.
Physician-Scientist Early Investigator
Molecular Imaging Program
NIH Distinguished Scholar
Head, Laboratory of Molecular Radiotherapy
Advances in engineering of tumor-specific molecules to guide cytotoxic treatments, such as chemotherapy or radionuclides, have resulted in new classes of cancer drugs which have the potential to kill tumors while mitigating toxicities to normal tissues, moving us closer to truly tumor-targeted, personalized cancer treatment for our patients. Targeted radionuclide therapy provides an orthogonal mode of cell killing that is distinct from, yet complementary to, existing small molecule and chemotherapy treatments. By harnessing systemic, targeted radionuclides, our group aims to develop new agents to help us better treat and monitor cancer patients. Dr. Escorcia is also a clinically trained radiation oncologist and treats patients with all tumor types amenable to radiation therapy. He is fluent in Spanish and English.
NIH Scientific Focus Areas: Biomedical Engineering and Biophysics, Chemical Biology, Clinical Research, Molecular Biology and Biochemistry, Molecular Pharmacology